May
22
2019
On demand

The power of ultra-high content and 3D imaging for the identification and characterisation of new CAR-T cell targets

CAR-T cells have been recently approved by numerous international drug agencies for the treatment of haematological malignancies with tremendous results. However, there is a lack of diversity of tumour-associated antigens with these CAR-T cell products. Identification and characterization of novel tumour antigens is required to expand tumour antigen repertoire that can be used with CAR-T or engineered TCR T cells into new malignancies, including solid tumours.

The focus of this On Demand Webinar is on new ultra-high content and 3D imaging technologies that enable you to rapidly and precisely identify and characterize novel tumour antigens. These novel tumour antigens can be used to discover new targets for CAR-T or engineered TCR T cells products.

Watch this On Demand with Dr Olaf Hardt, Manager R&D, Miltenyi Biotec GmbH and Dr Uwe Schröer, Senior Product Manager, LaVision BioTec GmbH, as they discuss:

  • Visualisation of hundreds of markers from one single sample using a new fully automated imaging process.
  • Light-sheet Microscopy for three-dimensional visualisation and characterization of tumour antigens in large tissue samples.
  • Testing and validating novel tumour antigens for cell and gene therapy.

Dr Olaf Hardt

Dr Olaf Hardt

Manager R&D, Miltenyi Biotec GmbH

Dr. Olaf Hardt is currently Manager R&D Oncology for Miltenyi Biotec in Bergisch Gladbach, Germany. His focus is on immuno-oncology preclinical research, target discovery, as well as oncology related product development. He also heads the transgenic unit and animal facility. He obtained his PhD at the University of Cologne, Germany in collaboration with Miltenyi Biotec and the IBDML in Marseille, France before he started as R&D Project Manager at Miltenyi Biotec in 2008.

Dr Uwe Schröer

Dr Uwe Schröer

Senior Product Manager, LaVision BioTec GmbH – A Miltenyi BioTec Company

Dr. Uwe Schröer is Senior Product Manager for Light Sheet Microscopy at LaVision BioTec located in Germany. He obtained his PhD from the Westfälische Wilhelms-Universität Münster where he characterized the regeneration of retinal ganglion cells. For his Diploma he was working at the “Rheinisch-Westfälischen Technischen Hochschule” Aachen in the field of molecular microbiology.

SPEAKERS

Olaf Hardt
Manager, R&D at Miltenyi Biotec
Uwe Schroeer
Product Manager at LaVision BioTec GmbH - A Miltenyi Biotec Company

You might also like

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
7
Hrs
51
Min
Register

Overcoming current challenges in immunotherapy drug development with...

S F. Boj
Sylvia  F. Boj
Sylvia F. Boj
Chief Scientific Officer at Hubrecht Institute
15 Jun 2022
27
Days
23
Hrs
51
Min
Register

Life on a chip - vascularized micro-tumor chips for mimicking clinical...

C Hughes
Chris Hughes
Chris Hughes
CSO at Aracari Biosciences
8 Jun 2022
20
Days
23
Hrs
51
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
12
Days
23
Hrs
51
Min
Register

Discovery to manufacturing: A continuum

A Chang,
T Hitchcock,
B Fry
Audrey Chang
Audrey Chang
Executive Director Quality Control & Analytical Sciences at Charles River Laboratories
Tony Hitchcock
Tony Hitchcock
Technical Director at Charles River Laboratories, Inc
Brian Fry
Brian Fry
Director, Sales - Biologics at Charles River Laboratories
5 April 2022
Watch now